The gap between guidelines and practice in the treatment of type 2 diabetes - A nationwide survey in Norway

被引:45
作者
Jenssen, Trond G. [1 ,6 ]
Tonstad, Serena [2 ]
Claudi, Tor [3 ]
Midthjell, Kristian [4 ]
Cooper, J. John [5 ]
机构
[1] Rikshosp Univ Hosp, N-0027 Oslo, Norway
[2] Ullevaal Univ Hosp, Oslo, Norway
[3] Ronvik Med Ctr, Bodo, Norway
[4] Norwegian Univ Sci & Technol, HUNT Res Ctr, Dept Family Med & Gen Practice, Verdal, Norway
[5] Stavanger Univ Hosp, Stavanger, Norway
[6] Univ Tromso, Inst Clin Med, Tromso, Norway
关键词
diabetes complications; metabolic syndrome; management;
D O I
10.1016/j.diabres.2007.12.025
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: In a nationwide sample of patients with type 2 diabetes we assessed the prevalence of complications and compliance with current guidelines. Methods: We recruited a randomly selected sample of 534 men and 441 women aged 18-75 years with type 2 diabetes. A single visit review of medical records, interview, physical examination and laboratory tests was collected. Results: The WHO criteria for the metabolic syndrome were met by 79% 174%, 84%]. Thirty percent [28%, 33%] had a history of cardiovascular disease, 13% [11%, 16%] had microalbuminuria, 15% [13%, 18%] had retinopathy, and 23% [21%, 26%] had peripheral neuropathy assessed by a monofilament test. Erectile dysfunction was common (43% [38%, 47%]). Two thirds met the national treatment target for glycaemia (HbA1c <7.5%), one-half the blood pressure target (BP <140/85 mmHg), and one-third the target for lipids (total/HDL cholesterol <4). However, only 13% reached the combined targets for glucose, blood pressure and cholesterol control. Conclusions: The classical microvascular complications of diabetes affected a minority of participants while the metabolic syndrome affected the majority. The gap between guidelines and current clinical practice was substantial given that only one of eight patients reached the combined goals for glycaemia, blood pressure and lipid control. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:314 / 320
页数:7
相关论文
共 24 条
[1]  
[Anonymous], 1999, Diabet Med, V16, P716
[2]   Kidney Early Evaluation Program (KEEP) - Findings from a community screening program [J].
不详 .
DIABETES EDUCATOR, 2004, 30 (02) :196-+
[3]  
CLAUDI T, 2000, NAMS GUID TREATM DIA
[4]  
Claudi Tor, 2004, Tidsskr Nor Laegeforen, V124, P1508
[5]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696
[6]  
Collins R, 2003, LANCET, V361, P2005
[7]   The gap between guidelines and reality:: Type 2 diabetes in a national diabetes register 1996-2003 [J].
Eliasson, B ;
Cederholm, J ;
Nilsson, P ;
Gudbjörnsdóttir, S .
DIABETIC MEDICINE, 2005, 22 (10) :1420-1426
[8]   Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes [J].
Gaede, P ;
Vedel, P ;
Larsen, N ;
Jensen, GVH ;
Parving, H ;
Pedersen, O .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (05) :383-393
[9]   IFCC reference system for measurement of hemoglobin Alc in human blood and the National Standardization Schemes in the United States, Japan, and Sweden:: A method-comparison study [J].
Hoelzel, W ;
Weykamp, C ;
Jeppsson, JO ;
Miedema, K ;
Barr, JR ;
Goodall, I ;
Hoshino, T ;
John, WG ;
Kobold, U ;
Little, R ;
Mosca, A ;
Mauri, P ;
Paroni, R ;
Susanto, F ;
Takei, I ;
Thienpont, L ;
Umemoto, M ;
Wiedmeyer, HM .
CLINICAL CHEMISTRY, 2004, 50 (01) :166-174
[10]   Cardiovascular morbidity and mortality associated with the metabolic syndrome [J].
Isomaa, B ;
Almgren, P ;
Tuomi, T ;
Forsén, B ;
Lahti, K ;
Nissén, M ;
Taskinen, MR ;
Groop, L .
DIABETES CARE, 2001, 24 (04) :683-689